MedTrace Logo

Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

NCT00142571 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2007-10-02

No results posted yet for this study

Summary

The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and docetaxel, to find out which treatment is better for people with sarcomas.

Conditions

  • Sarcoma, Soft Tissue

Interventions

DRUG

Gemcitabine

DRUG

Docetaxel

Sponsors & Collaborators

  • Connective Tissue Oncology Society

    collaborator OTHER

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • Mayo Clinic

    collaborator OTHER

  • University of Michigan Rogel Cancer Center

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Principal Investigators

  • Robert Maki, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00142571 on ClinicalTrials.gov